Ebos GroupASX:EBO +0.64%77 PEG Ratio is 1.76 as of Jul. 01, 2026, which is 19% below its 10-year median of 2.16. GuruFocus rates ASX:EBO with a GF Score™ of 77/100 and a GF Value™ of A$32.93 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 48 Medical Distribution companies, Ebos Group ranks worse than 54.17% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Ebos Group's PE Ratio without NRI is 15.11. Ebos Group's 5-Year EBITDA growth rate is 8.60%. Therefore, Ebos Group's PEG Ratio for today is 1.76.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Ebos Group's PEG Ratio or its related term are showing as below:
ASX:EBO'
s PEG Ratio Range Over the Past 10 Years
Min: 1.06 Med: 2.16 Max: 4.07
Current: 1.92
During the past 13 years, Ebos Group's highest PEG Ratio was 4.07. The lowest was 1.06. And the median was 2.16.
ASX:EBO's PEG Ratio is ranked worse than 54.17% of 48
companies
in the Medical Distribution industry
Industry Median: 1.84
vs ASX:EBO: 1.92
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Ebos Group (ASX:EBO) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Ebos Group PEG Ratio Related Terms
Ebos Group PEG Ratio Historical Data
* Premium members only.
The historical data trend for Ebos Group's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Ebos Group's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group PEG Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Ebos Group's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Ebos Group (ASX:EBO) has a PEG Ratio of 1.76 as of Jul. 01, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Ebos Group and its competitors. This is 19% below median its historical median of 2.16. Over the past decade, Ebos Group's PEG Ratio has ranged from 1.06 to 4.07. According to the industry distribution chart, Ebos Group ranks #26 out of 48 companies in the Medical Distribution industry, placing it in the top 54.2%.
Is Ebos Group's PEG Ratio too high?
Ebos Group's current PEG Ratio of 1.76 is 19% below median its 10-year median of 2.16. Over the past 10 years, this metric has ranged from a low of 1.06 to a high of 4.07. The Medical Distribution industry median PEG Ratio is 1.84. Ebos Group's value of 1.76 is 4.3% below this industry median. Based on the distribution chart, Ebos Group ranks #26 out of 48 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Ebos Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's PEG Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #26 out of 48 companies for PEG Ratio. This places Ebos Group in the lower half of its industry. The industry median PEG Ratio is 1.84. Ebos Group's value of 1.76 is 4.3% below this benchmark. Historically, Ebos Group's own PEG Ratio has ranged from 1.06 to 4.07 over the past decade. While the company's 10-year median is 2.16 vs. the industry median of 1.84, Ebos Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Distribution company?
The median PEG Ratio among Medical Distribution companies is 1.84, based on 48 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current PEG Ratio of 1.76 is 4.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median PEG Ratio is 1.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current PEG Ratio is 1.76, which is 19% below median its own 10-year median of 2.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$32.93, compared to a current price of A$17.18 — trading 47.8% below its estimated fair value. The current PEG Ratio is 1.76, which is 19% below median its 10-year median of 2.16 and 4.3% below the Medical Distribution industry median of 1.84. Ebos Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current PEG Ratio is 1.76 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (ASX:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of A$17.18 is trading 47.8% below its estimated GF Value™ of A$32.93.
GuruFocus considers Ebos Group to be Significantly Undervalued.
Key valuation signals for ASX:EBO:
PEG Ratio: 1.76 (19% below median its 10-year median of 2.16)
GF Value™: A$32.93 vs. price of A$17.18 (47.8% below fair value)
Industry Position: 4.3% below the Medical Distribution median (#26 of 48)
No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
77GF Score
Get the complete analysis for ASX:EBO
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EBO has been successfully added to your 
